Antimicrobial Peptide for the Treatment of Skin Diseases
- Detailed Technology Description
- None
- Supplementary Information
- Patent Number: US7459439B2
Application Number: US2005304911A
Inventor: Modlin, Robert L. | Kim, Jenny J. | Anderson, Daniel H. | Eisenberg, David S. | Gallo, Richard L.
Priority Date: 12 Sep 2003
Priority Number: US7459439B2
Application Date: 14 Dec 2005
Publication Date: 2 Dec 2008
IPC Current: A61K003800 | C07K001447
US Class: 5140011 | 514012 | 5140024
Assignee Applicant: The Regents of the University of California
Title: Granulysin peptides and methods of use thereof
Usefulness: Granulysin peptides and methods of use thereof
Summary: The granulysin peptide is useful for treating cutaneous microbial infection or inflammation (claimed). It is also useful for treating both early and late stages of inflammatory arthritis, non-infectious inflammatory arthropathy such as rheumatoid arthritis, bursitis, tendonitis, soft tissue injuries, Sjogren's syndrome, systemic lupus erythematous, psoriatic arthritis, gout and other crystalline arthropathies, capsulitis, carpal tunnel syndrome, myositis, polymyalgia, rheumatica, synovitis, Reiter's syndrome, erosive osteoarthritis, autoimmune diseases, inflammation caused by bacterial and viral infection, including response to vaccination, local inflammation in response to trauma, graft rejection, graft versus host disease, and inflammation after tooth extraction or gum disease.
Novelty: New isolated granulysin peptide comprising an alpha-helix turn alpha-helix motif and having amino acid substitution(s), useful for treating cutaneous microbial infection or inflammation
- Industry
- Biomedical
- Sub Category
- Pathogen
- Application No.
- 7459439
- Others
-
Additional Technologies by these Inventors
Tech ID/UC Case
21723/2004-087-0
Related Cases
2004-087-0
- *Abstract
-
Granulysin peptides are small antimicrobial agents with potent activity against bacteria and inflammation. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient suffering from a microbial infection.
- *IP Issue Date
- Dec 2, 2008
- *Principal Investigator
-
Name: Daniel Anderson
Department:
Name: David Eisenberg
Department:
Name: Richard Gallo
Department:
Name: Richard Gallo
Department:
Name: Jenny Kim
Department:
Name: Robert Modlin
Department:
- Country/Region
- USA
For more information, please click Here
